Common questions about Caverject Dual (FAQ)
Q: What is the main difference in mechanism between this treatment and oral ED pills?
Official product information describes this medication as containing alprostadil, a prostaglandin E1 analog. Its mechanism is local, acting directly on blood vessels in the penis to cause smooth muscle relaxation and increased blood flow.
This differs from oral treatments (PDE5 inhibitors), which typically work systemically by blocking an enzyme involved in the natural process of smooth muscle relaxation.
Q: Is a burning sensation or discomfort common after injection?
According to official regulatory documents, penile pain is classified as a very common side effect, affecting more than 1 in 10 users in clinical trials. This pain is often described as mild or moderate discomfort.
Pain or discomfort specifically at the site where the injection is given is also reported as a common adverse reaction.
Q: How quickly does it start working after the injection?
Studies and official information indicate that the injection is generally expected to start its effect within 5 to 20 minutes of administration.
The duration of the effect is established as part of the individualized dosing process.
Q: Can I use this if I take oral blood pressure medication?
Official regulatory sources note that the active ingredient can cause a transient increase in systemic blood levels, which may result in a drop in blood pressure (hypotension).
The consideration of use in patients with cardiovascular conditions or those taking medications that affect blood pressure is noted in regulatory documents.
Q: What are the excipients (inactive ingredients) in the solution?
The components of the reconstituted solution include the active ingredient, alprostadil, along with several inactive ingredients (excipients).
Official product labels list excipients such as alpha cyclodextrin, lactose, sodium citrate, and benzyl alcohol in the powder, and bacteriostatic water for injection as the solvent.
Q: Are there any official guidelines for traveling with the medicine?
Official regulatory documents define strict storage conditions for the unreconstituted powder, which must be kept within a temperature range of 20 C to 25 C.
Following these temperature guidelines helps maintain the product's integrity during transportation, as extreme temperatures may affect the medicine.
Q: Does this treatment carry a risk of developing Peyronie's disease?
Regulatory documents indicate that penile fibrosis (the development of scar tissue), fibrotic nodules, penile angulation, and Peyronie's disease have been reported as adverse reactions.
The regulatory label specifies that patients should be regularly examined for signs of penile fibrosis, and treatment discontinuation is a requirement if these conditions develop.
Q: What is the reported success rate (numerical percentage) in clinical trials?
Regulatory summaries of clinical trials do not typically provide a single numerical success rate percentage for general use.
However, following individualized dose adjustment, the study data indicate an association with the achievement of an erection suitable for the primary end-point in a majority of the patients studied.
Q: Does the efficacy of the injection reduce or remain the same over time?
Official post-marketing surveillance reports include cases where a reduction in the drug's effect was noted by users, using terms such as 'drug effect decreased' or 'drug ineffective.'
This suggests that some patients may experience a reduction in the expected response over time.
Q: Should I avoid driving or operating machinery after using the injection?
Official regulatory information does not state that the medicine directly impacts the ability to drive or operate machinery.
However, because systemic side effects like dizziness, fainting (syncope), or a vasovagal reaction can occur, it is noted that due to the potential for these effects, particular attention may be required after administration, especially during initial use.
Q: Is a pre-filled, single-chamber version of this medication available?
This medicine is supplied as a unique 'dual' chamber system.
This specialized form consists of two separate compartments within the syringe device—one containing the powder and one containing the liquid solvent—that must be mixed immediately prior to injection.
Q: Are there known interactions with supplements like L-arginine or ginseng?
Formal clinical studies examining the drug's interaction potential with food supplements, such as L-arginine or ginseng, have not been specifically conducted.
Official labeling primarily restricts co-administration with other vasoactive agents that are injected locally, citing unstudied safety risks.
Q: What should I do if the solution looks cloudy or discolored after mixing?
Official product documentation states that the medicine, once prepared, should be a clear, colorless liquid solution.
If the solution appears to be cloudy, discolored, or contains any floating particles, regulatory guidelines state that the product should not be injected and that appropriate disposal according to regulated instructions is required.
Q: Is it safe to consume alcohol before or after using the injection?
There have been no formal studies conducted to determine specific interactions between this medication and alcohol consumption.
Due to the possibility of hypotension, regulatory information suggests consideration is necessary when combining it with any substance, such as alcohol, that may also cause vasodilation.
Q: Does the injection affect urine flow or bladder function?
Official regulatory documentation lists several uncommon adverse reactions related to the urinary system.
These include reports of painful urination (dysuria), blood in the urine (hematuria), increased frequency of urination (pollakiuria), and urethral hemorrhage.
Q: Does the use of the injection affect orgasm and ejaculation?
According to the official regulatory safety profile, adverse reactions reported in clinical trials include abnormal ejaculation and ejaculation disorder.
This information is included in the list of known undesirable effects.
